Anti-Parkinsonian Therapy: Strategies for Crossing the Blood-Brain Barrier and Nano-Biological Effects of Nanomaterials

Overview

Journal Nanomicro Lett

Publisher Springer

Date 2022 Apr 15

PMID 35426525

Authors

Guowang Cheng

Yujing Liu

Rui Ma

Guopan Cheng

Yucheng Guan

Xiaojia Chen

Zhenfeng Wu

Tongkai Chen

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD), a neurodegenerative disease that shows a high incidence in older individuals, is becoming increasingly prevalent. Unfortunately, there is no clinical cure for PD, and novel anti-PD drugs are therefore urgently required. However, the selective permeability of the blood-brain barrier (BBB) poses a huge challenge in the development of such drugs. Fortunately, through strategies based on the physiological characteristics of the BBB and other modifications, including enhancement of BBB permeability, nanotechnology can offer a solution to this problem and facilitate drug delivery across the BBB. Although nanomaterials are often used as carriers for PD treatment, their biological activity is ignored. Several studies in recent years have shown that nanomaterials can improve PD symptoms via their own nano-bio effects. In this review, we first summarize the physiological features of the BBB and then discuss the design of appropriate brain-targeted delivery nanoplatforms for PD treatment. Subsequently, we highlight the emerging strategies for crossing the BBB and the development of novel nanomaterials with anti-PD nano-biological effects. Finally, we discuss the current challenges in nanomaterial-based PD treatment and the future trends in this field. Our review emphasizes the clinical value of nanotechnology in PD treatment based on recent patents and could guide researchers working in this area in the future.

Citing Articles

Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology.

Dhariwal R, Jain M, Mir Y, Singh A, Jain B, Kumar P Front Med (Lausanne). 2025; 12:1522223.

PMID: 39963432 PMC: 11831571. DOI: 10.3389/fmed.2025.1522223.

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.

Functional Monomers Equipped Microgel System for Managing Parkinson's Disease by Intervening Chemokine Axis-mediated Nerve Cell Communications.

Jiang L, Zhang X, Wang S, Zhang J, Chen J, Lu J Adv Sci (Weinh). 2024; 12(7):e2410070.

PMID: 39721010 PMC: 11831437. DOI: 10.1002/advs.202410070.

HDAC6 inhibitor-loaded brain-targeted nanocarrier-mediated neuroprotection in methamphetamine-driven Parkinson's disease.

Pham K, Khanal S, Bohara G, Rimal N, Song S, Nguyen T Redox Biol. 2024; 79():103457.

PMID: 39700694 PMC: 11722933. DOI: 10.1016/j.redox.2024.103457.

Single-atom nanozyme liposome-integrated microneedles for in situ drug delivery and anti-inflammatory therapy in Parkinson's disease.

Liu Y, Liu Y, Shi P, Hu X, Fan X, Wu Y J Nanobiotechnology. 2024; 22(1):643.

PMID: 39427214 PMC: 11490154. DOI: 10.1186/s12951-024-02924-4.

References

Xiong S, Li Z, Liu Y, Wang Q, Luo J, Chen X . Brain-targeted delivery shuttled by black phosphorus nanostructure to treat Parkinson's disease. Biomaterials. 2020; 260:120339. DOI: 10.1016/j.biomaterials.2020.120339. View

Liu Y, Bhattarai P, Dai Z, Chen X . Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2018; 48(7):2053-2108. PMC: 6437026. DOI: 10.1039/c8cs00618k. View

Marcos-Contreras O, Brenner J, Kiseleva R, Zuluaga-Ramirez V, Greineder C, Villa C . Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain. J Control Release. 2019; 301:54-61. PMC: 6510023. DOI: 10.1016/j.jconrel.2019.03.008. View

Liu Y, Zhu D, Luo J, Chen X, Gao L, Liu W . NIR-II-Activated Yolk-Shell Nanostructures as an Intelligent Platform for Parkinsonian Therapy. ACS Appl Bio Mater. 2022; 3(10):6876-6887. DOI: 10.1021/acsabm.0c00794. View

Shuvaev V, Han J, Yu K, Huang S, Hawkins B, Madesh M . PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J. 2010; 25(1):348-57. PMC: 3005426. DOI: 10.1096/fj.10-169789. View

Bi C, Wang A, Chu Y, Liu S, Mu H, Liu W . Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment. Int J Nanomedicine. 2016; 11:6547-6559. PMC: 5153272. DOI: 10.2147/IJN.S120939. View

Marcos-Contreras O, Greineder C, Kiseleva R, Parhiz H, Walsh L, Zuluaga-Ramirez V . Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier. Proc Natl Acad Sci U S A. 2020; 117(7):3405-3414. PMC: 7035611. DOI: 10.1073/pnas.1912012117. View

Barker R, Gotz M, Parmar M . New approaches for brain repair-from rescue to reprogramming. Nature. 2018; 557(7705):329-334. DOI: 10.1038/s41586-018-0087-1. View

Furtado D, Bjornmalm M, Ayton S, Bush A, Kempe K, Caruso F . Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Adv Mater. 2018; 30(46):e1801362. DOI: 10.1002/adma.201801362. View

10.

Oller-Salvia B, Sanchez-Navarro M, Giralt E, Teixido M . Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem Soc Rev. 2016; 45(17):4690-707. DOI: 10.1039/c6cs00076b. View

11.

Biju K, Santacruz R, Chen C, Zhou Q, Yao J, Rohrabaugh S . Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Neurosci Lett. 2013; 535:24-9. PMC: 3645298. DOI: 10.1016/j.neulet.2012.12.034. View

12.

Liu L, Li M, Xu M, Wang Z, Zeng Z, Li Y . Actively targeted gold nanoparticle composites improve behavior and cognitive impairment in Parkinson's disease mice. Mater Sci Eng C Mater Biol Appl. 2020; 114:111028. DOI: 10.1016/j.msec.2020.111028. View

13.

Bengoa-Vergniory N, Roberts R, Wade-Martins R, Alegre-Abarrategui J . Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 2017; 134(6):819-838. PMC: 5663814. DOI: 10.1007/s00401-017-1755-1. View

14.

Mosquera J, Garcia I, Liz-Marzan L . Cellular Uptake of Nanoparticles versus Small Molecules: A Matter of Size. Acc Chem Res. 2018; 51(9):2305-2313. DOI: 10.1021/acs.accounts.8b00292. View

15.

Villar-Pique A, da Fonseca T, Outeiro T . Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. J Neurochem. 2015; 139 Suppl 1:240-255. DOI: 10.1111/jnc.13249. View

16.

Liaw K, Zhang Z, Kannan S . Neuronanotechnology for brain regeneration. Adv Drug Deliv Rev. 2019; 148:3-18. DOI: 10.1016/j.addr.2019.04.004. View

17.

Li Y, Chen Z, Lu Z, Yang Q, Liu L, Jiang Z . "Cell-addictive" dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway. Theranostics. 2018; 8(19):5469-5481. PMC: 6276100. DOI: 10.7150/thno.28295. View

18.

Qu M, Lin Q, Huang L, Fu Y, Wang L, He S . Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease. J Control Release. 2018; 287:156-166. DOI: 10.1016/j.jconrel.2018.08.035. View

19.

Gan L, Li Z, Lv Q, Huang W . Rabies virus glycoprotein (RVG29)-linked microRNA-124-loaded polymeric nanoparticles inhibit neuroinflammation in a Parkinson's disease model. Int J Pharm. 2019; 567:118449. DOI: 10.1016/j.ijpharm.2019.118449. View

20.

Vissers C, Ming G, Song H . Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders. Adv Drug Deliv Rev. 2019; 148:239-251. PMC: 6703981. DOI: 10.1016/j.addr.2019.02.007. View